Introduction: Results: Methodology: Discussion: Conclusion:

Slides:



Advertisements
Similar presentations
Optimisation of combination therapy for treatment of Pseudomonas aeruginosa Alex Cochrane Bristol Centre for Antimicrobial Research and Evaluation University.
Advertisements

A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Figure 1: Differential in MICs for common C. difficile ribotypes Introduction Clostridium difficile has been identified as the primary cause of nosocomial.
Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy Yang Xin Paper presentation PNAS 2009, 106(12):
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Relationship between Daptomycin (DAP) Free drug AUC/MIC, Antibacterial effect (ABE) and Emergence of Resistance (EoR) in S.aureus. KE Bowker, AR Noel,
PHL 424 Antimicrobials 1 st Lecture By Abdelkader Ashour, Ph.D. Phone:
Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.
PHL 521 Clinical Dental Therapeutics 1 st Lecture By Abdelkader Ashour, Ph.D. Phone:
Antibiotics Biotechnology II. Univ S. Carolina Antibiotics Disrupt Cell Wall Synthesis, Protein Synthesis, Nucleic Acid Synthesis and Metabolism.
Susceptibility of Drug Resistant Acinetobacter baumanii (DRAB) to a stabilized aqueous allicin extract from garlic (AB1000 ). Researchers’/Presenters’
Carbapenem Activity Against Acinetobacter calcoaceticus-baumanii complex (ACBC) in an In Vitro Pharmacokinetic Bacteremia Model (PKM) Eric G Sahloff, Pharm.D.,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Synergism : what does it mean? JW Mouton Dept Medical Microbiology Canisius Wilhelmina Hospital Nijmegen, The Netherlands.
Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.
Aims of study This surveillance study was performed to determine the in vitro activity of ciprofloxacin against clinical isolates of Escherichia coli and.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
Colimix 120 Sintofarm (Colistin sulphate). Colistin is a polypeptide antibiotic, was obtained from a fermentation broth inoculated with Bacillus polimyxa.
Relationship between Time to Eradication in vivo & Bactericidal Activity in vitro of Vancomycin for MRSA Infections Pamela A. Moise-Broder Alan Forrest.
DENS 521 Clinical Dental Therapeutics 1 st Lecture By Abdelkader Ashour, Ph.D. Phone:
1 Developments in pK/pD: optimising efficacy & prevention of resistance A critical review of pK/pD in in vitro models Alasdair MacGowan Bristol Centre.
Christine Hesje, BSc; Joseph M. Blondeau, PhD
Supplemental testing methods
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis and first/second line treatments Dr Andrew Dodgson Consultant Microbiologist.
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.
The Efficacy of Topical Manuka Honey and Combination Antibiotic Therapy in the Treatment of MRSA Skin Infections Kyle Liban Pacific University School of.
Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of.
REVISED ABSTRACT Background: Omadacycline (OMC) is the first of a new class of tetracyclines, the aminomethylcyclines, and is being developed as a once-daily.
Susceptibility of Drug Resistant Acinetobacter baumanii (DRAB) to a stabilized aqueous allicin extract from garlic (AB1000 ). Researchers’/Presenters’
Tapasyapreeti Mukhopadhyay, Vrushali Patwardhan, Sarman Singh
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
The aminoglycoside antibiotics
Use of antibiotics.
Antimicrobial Susceptibility Testing (AST)
Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.
carbapenemase-positive Enterobacteriaceae
JM Tyrrell1, M. Woodward2, RA. Howe3, TR. Walsh1
ANIBIOTICS AND CHEMOTHERAPUETIC AGENTS (I)
Introduction to Lab Ex. 14: Antibiotic Sensitivity
R. Leclercq  Clinical Microbiology and Infection 
Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli,
Principles of Antimicrobial use and Drug Resistance Omilabu S.A, Ph.D Department of Medical Microbiology and Parasitology, CMUL. 16 th January 2015.
Bad bugs, no drugs and no ESKAPE RESULTS: In vitro experimental data
Correspondence: Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae M. Albur, A. Noel, K. Bowker, A.
Prevalence of CTX-M-14 type in Welsh Hospitals
in Broth Microdilution Method. M. Albur, A. Noel, K. Bowker, A
F th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC The Activity of RTA-3, a Novel Antimicrobial.
Antibiotic Susceptibility Testing
A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Cross-resistance to human cationic antimicrobial peptides and to polymyxins mediated by the plasmid-encoded MCR-1?  J. Dobias, L. Poirel, P. Nordmann 
Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae  M. Ballestero-Téllez,
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Examining Temocillin Activity in Combination.
Chemotherapeutic agent
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H
Enhanced antimicrobial activity of peptide-cocktails against common bacterial contaminants of ex vivo stored platelets  K.V.K. Mohan, S. Sainath Rao,
M.R. Jacobs  Clinical Microbiology and Infection 
Clinical Microbiology Conference 2017
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan 
Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions  Gerard McCaughey,
The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model  Alasdair P. MacGowan,
Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents    Clinical Microbiology and Infection  Volume.
Discussion and Future Work
Principles of Antimicrobial Therapy
Presentation transcript:

Introduction: Results: Methodology: Discussion: Conclusion: Bactericidal Activity of Multiple Combinations of Fosfomycin and Colistin against NDM-1 producing Enterobacteriaceae M. Albur, A. Noel, K. Bowker, A. MacGowan BCARE, Department of Microbiology, North Bristol NHS Trust, Bristol, UK E-793 Table 2. Area under the bacterial kill curve (AUBKC) of the isolates Introduction: Results: AUBKC (0-48hr) (log CFU/ml/hr) Fosfomycin sensitive strains (meanSD) AUBKC (0-48hr) (log CFU/ml/hr) Fosfomycin resistant strains (meanSD ) FM 0mg/L FM 5mg/L FM 20mg/L FM 250mg/L CS 0 mg/L 360.630.5 297.820.6 268.823.2 23.81.6 365.814.7 364.29.6 341.420.4 282.422.4 0.10 mg/L 340.534.5 208.7160 184.6123 24.310.8 350.123 36513 334.632.2 108.5157.2 0.16 mg/L 332.218.9 113.4148 102.181.8 34.27.9 358.218 341.934.2 323.946.1 134.3142.4 0.29 mg/L 307.45.7 37.213.2 29.23.3 21.39.3 311.720.1 316.922 168139.6 107.9156.6 CMS 365.319 295.928.9 265.913.5 27.27.8 371.214.1 360.925.9 34525.7 28030.8 2.1 mg/L 366.317.1 32.41.6 30.11.9 23.37.6 363.117.9 369.530.8 322.244.3 105.973.2 2.7 mg/L 325.215.1 30.63.6 29.53 27.22.3 352.337.6 326.561.3 282.357.1 168.2120.7 8.5 mg/L 242.646.1 22.37.2 21.56.6 2210.5 261.353.8 255.433 159.4126 20.47.5 Therapeutic options against NDM-1 producing Enterobactericeae are limited. Colistin, fosfomycin, and tigecycline are some of the agents where many strains still have MICs below the clinical breakpoint. Fosfomycin and colistin act on bacterial cells by different mechanisms. Hence there is a potential scope for both antagonism as well as synergism. The comparative mean TKC of both individual and various combinations of antimicrobials at different concentrations are shown in Fig 1, 2, & 3. Both colistin and FM showed concentration dependent bactericidal activity at all concentrations ( ≈ 3-4 log kill at 3hrs at peak concentration). Combinations of FM with CS/CMS produced lower AUBKC as compared to individual agent (i.e. increased cidality/synergy) [Table 2]. As expectedly, the degree of increased bacterial killing was more pronounced against FM sensitive strains compared to FM resistant strains. Methodology: Bactericidal activity of fosfomycin (FM), Colistin sulphate (CS), and Colistin methanesulfonate (CMS) was assessed by time-kill methodology. 6 well characterised strains of NDM-1 producing Enterobacteriaceae were used [Table 1]. Three of them were sensitive and three were resistant to FM. Pharmacokinetically achievable free drug serum concentrations were used. The following concentrations reflecting peak (Cmax), average (Css), and trough (Cmin) concentrations expressed in mg/L were used respectively for FM (250, 20, 5), CS (0.29, 0.16, 0.1) and CMS (8.5, 2.7, 2.1). A 44 drug exposure matrix of FM with CS and CMS were used along with a growth control (GC) at 0, 1, 3, 6, 12, 24 and 48 hr time-points. Fig. 1a Fig. 1b Discussion: Due to increase in antimicrobial resistance amongst Gram-negative bacteria, combination therapy is gaining importance. This is based on an assumption that combination therapy not only increases the efficacy (in terms of killing & spectrum) but also prevents emergence of secondary resistance on monotherapy. This study show that the addition of FM to colistin (the primary drug of choice against MDR Gram negative bacteria) produces increased bacterial killing at all therapeutically achievable concentrations even for FM resistant strains. There was no evidence of antagonism even against FM resistant strains. Fig. 2a Fig. 2b Table 1 MICs of the isolates Isol. No. Isolate ID FM MIC Colistin 45836 E. coli 1 0.38 45838 K. pneumoniae >128 0.125 45839 K. oxytoca 0.094 45840 45841 4 45842 0.5 Fig. 3a Fig. 3b Conclusion: Combination of fosfomycin and colistin produced increased bacterial killing against NDM-1 producing Enterobacteriaceae with no evidence of antagonism even against FM resistant strains.